Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
(2015) In Haematologica 100(1). p.107-113- Abstract
- Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To estimate the risk of bacterial and viral infections in multiple myeloma patients, we used population-based data from Sweden to identify all multiple myeloma patients (n=9 253) diagnosed from 1988 to 2004 with follow-up to 2007 and 34 931 matched controls. Cox proportional hazard models were used to estimate the risk of infections. Overall, multiple myeloma patients had a 7-fold (hazard ratio =7.1; 95% confidence interval = 6.8-7.4) risk of developing any infection compared to matched controls. The increased risk of developing a bacterial infection was 7-fold (7.1; 6.8-7.4), and for viral infections 10-fold (10.0; 8.9-11.4). Multiple myeloma... (More)
- Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To estimate the risk of bacterial and viral infections in multiple myeloma patients, we used population-based data from Sweden to identify all multiple myeloma patients (n=9 253) diagnosed from 1988 to 2004 with follow-up to 2007 and 34 931 matched controls. Cox proportional hazard models were used to estimate the risk of infections. Overall, multiple myeloma patients had a 7-fold (hazard ratio =7.1; 95% confidence interval = 6.8-7.4) risk of developing any infection compared to matched controls. The increased risk of developing a bacterial infection was 7-fold (7.1; 6.8-7.4), and for viral infections 10-fold (10.0; 8.9-11.4). Multiple myeloma patients diagnosed in the more recent calendar periods had significantly higher risk of infections compared to controls (p<0.001). At one year of follow-up, infection was the underlying cause in 22% of deaths in multiple myeloma patients. Mortality due to infections remained constant during the study period. Our findings confirm that infections represent a major threat to multiple myeloma patients. The effect on infectious complications due to novel drugs introduced in the treatment of multiple myeloma needs to be established and trials on prophylactic measures are needed. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4733270
- author
- Blimark, Cecilie ; Holmberg, Erik ; Mellqvist, Ulf-Henrik ; Landgren, Ola ; Björkholm, Magnus ; Hultkrantz, Malin L ; Kjellander, Christian ; Turesson, Ingemar LU and Kristinsson, Sigurdur Y
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Haematologica
- volume
- 100
- issue
- 1
- pages
- 107 - 113
- publisher
- Ferrata Storti Foundation
- external identifiers
-
- pmid:25344526
- wos:000351278500030
- scopus:84920175072
- pmid:25344526
- ISSN
- 1592-8721
- DOI
- 10.3324/haematol.2014.107714
- language
- English
- LU publication?
- yes
- id
- f885b300-ec03-4e9e-80e7-ae8720c2f355 (old id 4733270)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25344526?dopt=Abstract
- date added to LUP
- 2016-04-01 10:51:13
- date last changed
- 2022-04-28 01:51:11
@article{f885b300-ec03-4e9e-80e7-ae8720c2f355,
abstract = {{Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To estimate the risk of bacterial and viral infections in multiple myeloma patients, we used population-based data from Sweden to identify all multiple myeloma patients (n=9 253) diagnosed from 1988 to 2004 with follow-up to 2007 and 34 931 matched controls. Cox proportional hazard models were used to estimate the risk of infections. Overall, multiple myeloma patients had a 7-fold (hazard ratio =7.1; 95% confidence interval = 6.8-7.4) risk of developing any infection compared to matched controls. The increased risk of developing a bacterial infection was 7-fold (7.1; 6.8-7.4), and for viral infections 10-fold (10.0; 8.9-11.4). Multiple myeloma patients diagnosed in the more recent calendar periods had significantly higher risk of infections compared to controls (p<0.001). At one year of follow-up, infection was the underlying cause in 22% of deaths in multiple myeloma patients. Mortality due to infections remained constant during the study period. Our findings confirm that infections represent a major threat to multiple myeloma patients. The effect on infectious complications due to novel drugs introduced in the treatment of multiple myeloma needs to be established and trials on prophylactic measures are needed.}},
author = {{Blimark, Cecilie and Holmberg, Erik and Mellqvist, Ulf-Henrik and Landgren, Ola and Björkholm, Magnus and Hultkrantz, Malin L and Kjellander, Christian and Turesson, Ingemar and Kristinsson, Sigurdur Y}},
issn = {{1592-8721}},
language = {{eng}},
number = {{1}},
pages = {{107--113}},
publisher = {{Ferrata Storti Foundation}},
series = {{Haematologica}},
title = {{Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.}},
url = {{https://lup.lub.lu.se/search/files/2186437/7583367.pdf}},
doi = {{10.3324/haematol.2014.107714}},
volume = {{100}},
year = {{2015}},
}